Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:CLRB NASDAQ:LPCN NASDAQ:PCSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.31+0.5%$1.49$0.77▼$2.35$20.91M0.52181,759 shs136,268 shsCLRBCellectar Biosciences$2.74+5.2%$2.81$2.20▼$6.52$21.85M0.51562,005 shs72,815 shsLPCNLipocine$2.48-0.2%$2.30$1.81▼$12.37$20.47M0.48265,307 shs6,244 shsPCSAHeatwurx$1.91-1.3%$2.53$1.76▼$14.24$5.26M162,289 shs39,198 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%-4.41%-20.73%+19.27%+30.01%CLRBCellectar Biosciences+2.97%+1.17%-17.20%+2.36%-67.09%LPCNLipocine+1.22%+8.73%+10.67%-68.84%-24.32%PCSAHeatwurx+4.30%-6.73%-24.22%-23.32%-60.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.31+0.5%$1.49$0.77▼$2.35$20.91M0.52181,759 shs136,268 shsCLRBCellectar Biosciences$2.74+5.2%$2.81$2.20▼$6.52$21.85M0.51562,005 shs72,815 shsLPCNLipocine$2.48-0.2%$2.30$1.81▼$12.37$20.47M0.48265,307 shs6,244 shsPCSAHeatwurx$1.91-1.3%$2.53$1.76▼$14.24$5.26M162,289 shs39,198 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%-4.41%-20.73%+19.27%+30.01%CLRBCellectar Biosciences+2.97%+1.17%-17.20%+2.36%-67.09%LPCNLipocine+1.22%+8.73%+10.67%-68.84%-24.32%PCSAHeatwurx+4.30%-6.73%-24.22%-23.32%-60.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 2.00Hold$10.25684.84% UpsideCLRBCellectar Biosciences 2.50Moderate Buy$11.00302.19% UpsideLPCNLipocine 2.33Hold$15.00503.86% UpsidePCSAHeatwurx 2.00Hold$25.001,206.17% UpsideCurrent Analyst Ratings BreakdownLatest PCSA, ALLR, CLRB, and LPCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026ALLRAllarity Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.75 ➝ $10.255/15/2026CLRBCellectar Biosciences LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026PCSAHeatwurx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ALLRAllarity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026ALLRAllarity Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.50 ➝ $9.754/6/2026LPCNLipocine HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity Therapeutics$345K60.23N/AN/A$0.61 per share2.14CLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/ALPCNLipocine$1.98M10.34N/AN/A$2.61 per share0.95PCSAHeatwurxN/AN/AN/AN/A$2.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.23M-$0.72N/AN/AN/AN/A-109.94%-47.27%8/21/2026 (Estimated)CLRBCellectar Biosciences-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)LPCNLipocine-$9.63M-$1.88N/AN/AN/A-571.18%-66.70%-59.39%8/4/2026 (Estimated)PCSAHeatwurx-$13.56M-$9.29N/AN/AN/AN/A-281.31%-200.80%8/6/2026 (Estimated)Latest PCSA, ALLR, CLRB, and LPCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ALLRAllarity Therapeutics-$0.22-$0.17+$0.05-$0.17$0.03 million$0.03 million5/14/2026Q1 2026CLRBCellectar Biosciences-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A5/7/2026Q1 2026LPCNLipocine-$0.51-$0.54-$0.03-$0.54$0.16 million$0.12 million3/30/2026Q4 2025ALLRAllarity Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A1.231.23CLRBCellectar BiosciencesN/A1.901.90LPCNLipocineN/A9.999.99PCSAHeatwurxN/A0.980.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%CLRBCellectar Biosciences16.41%LPCNLipocine9.11%PCSAHeatwurx91.93%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.16%CLRBCellectar Biosciences2.58%LPCNLipocine6.35%PCSAHeatwurx3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.91 million15.89 millionNot OptionableCLRBCellectar Biosciences107.99 million7.79 millionNo DataLPCNLipocine108.24 million7.72 millionNo DataPCSAHeatwurx202.77 million2.67 millionNot OptionablePCSA, ALLR, CLRB, and LPCN HeadlinesRecent News About These CompaniesProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2026 | globenewswire.comProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer StudyJanuary 5, 2026 | globenewswire.comPCSA Stock Soars on Upbeat Clinical Update From Breast Cancer StudyDecember 18, 2025 | zacks.comProcessa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast CancerDecember 17, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025November 5, 2025 | globenewswire.comProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesAugust 7, 2025 | globenewswire.comProcessa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for GastroparesisJune 17, 2025 | quiverquant.comQProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International ConventionJune 15, 2025 | nasdaq.comProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025June 13, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCSA, ALLR, CLRB, and LPCN Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.31 +0.01 (+0.46%) As of 02:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Cellectar Biosciences NASDAQ:CLRB$2.74 +0.14 (+5.19%) As of 02:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Lipocine NASDAQ:LPCN$2.48 -0.01 (-0.24%) As of 02:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Heatwurx NASDAQ:PCSA$1.91 -0.03 (-1.34%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Wall Street Still Sees Massive Upside for AeroVironment Stock Manchester United’s Stock Rally Faces a Test Beyond Old Trafford Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying Volkswagen’s 16-Year Low Masks a Massive Margin Engine Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat Overclocking Qualcomm: Rewiring the AI Compute Market SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
